Drug Search Results
More Filters [+]

Vestipitant

Alternative Names: vestipitant, gw-597599, gw597599, gw 597599
Latest Update: 2021-08-13
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vestipitant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Tinnitus|Deafness|Phobia, Social|Hearing Loss|Insomnia|Depressive Disorder|Generalized anxiety disorder|Other|Anesthesia Related|Parasomnias

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-005216-28

P2

Terminated

Unknown

2012-08-22

VNK115640

P2

Completed

Other

2012-08-01

VNK114995

P1

Completed

Healthy Volunteers

2011-10-01

2008-006345-72

P2

Completed

Insomnia

2009-09-21

Recent News Events